Evommune (EVMN) Stifel 2026 Healthcare Conference 2026 summary

Portfolio and priorities

• Portfolio spans inflammatory disease mechanisms and modalities; programs are assessed for biological rationale, clinical and regulatory path, and medical and commercial opportunity. Discovery includes STAT6 degraders and inhibitors, with candidate selection targeted for 2027.

• EVO301 is planned for a phase IIb atopic dermatitis study in mid-2027 and a phase IIa ulcerative colitis study beginning early 2027; EVO756 is being developed in migraine, and EVO646 is advancing toward phase I.

• Funding was expected to support planned catalysts through the end of 2029.

EVO301 and IL-18

• IL-18 is viewed as an upstream inflammatory target affecting Th2, Th1, Th17 and Th22 pathways; the fusion protein uses natural IL-18 binding protein and an albumin Fab for extended half-life.

• Phase IIa atopic dermatitis data showed EASI reductions after doses on days 1 and 29, with efficacy continuing to improve through week 12; biomarkers reflected effects across Th2, Th1, Th17 and Th22 pathways.

• The phase IIb study is planned as a full dose-range-finding study; a high-concentration subcutaneous formulation showed favorable bioavailability versus IV in non-human primates and may support dosing every four weeks.

• Binding studies found no measurable or appreciable binding to IL-1β or IL-37; the team reported no evidence of interference with shared-receptor biology.

• The planned UC phase IIa is a placebo-controlled study of fewer than 100 patients using IV formulation; rationale includes genetic evidence and potential effects on mucosal barrier function.

EVO646 and TLR7/8

• EVO646 is an oral TLR7/8 small molecule developed with Accutar, with once-daily dosing; phase I with a full biomarker plan is expected in 2027, with data toward year-end.

• Phase I data are expected by end-2027, with potential proof-of-concept studies starting around the same timeframe; lupus, myasthenia gravis and thyroid eye disease were cited as potential indications.

• The team sees once-daily dosing as a differentiator from first-generation molecules and plans to use biomarker results and clinical validation to guide indication selection.